Juventas Closes $62 Million C Round for CAR-T/Stem Cells/Gene Editing
July 19, 2021 at 05:37 AM EDT
Juventas Cell Therapy of Beijing closed a Series C financing of over $62 million to develop its lead CAR-T candidate, stem cell (iPSCs) technology and gene editing platform. In 2019, Juventas out-licensed global rights to CNCT19, a CD19 CAR-T treatment, to CASI Pharma in return for an $11.6 million CASI investment. Juventas remains in control of clinical trials of the CAR-T in leukemia and lymphoma patients. The C round was jointly led by CICC Capital's fund and Oceanpine Healthcare Fund. More details.... Share this with colleagues: // //